QRG Capital Management Inc. Buys 198,951 Shares of Boston Scientific Corporation $BSX

QRG Capital Management Inc. lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 121.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 362,716 shares of the medical equipment provider’s stock after acquiring an additional 198,951 shares during the period. QRG Capital Management Inc.’s holdings in Boston Scientific were worth $15,481,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of BSX. Fisher Funds Management LTD grew its holdings in Boston Scientific by 17.1% in the second quarter. Fisher Funds Management LTD now owns 1,007,864 shares of the medical equipment provider’s stock worth $43,016,000 after purchasing an additional 146,900 shares during the period. Congress Park Capital LLC acquired a new position in shares of Boston Scientific during the second quarter valued at about $224,000. Portside Wealth Group LLC bought a new position in shares of Boston Scientific during the 2nd quarter worth about $263,000. Trust Asset Management LLC grew its stake in shares of Boston Scientific by 2.0% in the 2nd quarter. Trust Asset Management LLC now owns 16,666 shares of the medical equipment provider’s stock valued at $711,000 after buying an additional 333 shares during the period. Finally, Toth Financial Advisory Corp grew its stake in shares of Boston Scientific by 569.1% in the 2nd quarter. Toth Financial Advisory Corp now owns 823 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 700 shares during the period. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney purchased 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 204,322 shares of company stock worth $9,939,221 over the last ninety days. Company insiders own 0.34% of the company’s stock.

Boston Scientific Stock Up 0.4%

Boston Scientific stock opened at $51.40 on Thursday. The firm has a 50 day moving average price of $45.94 and a 200-day moving average price of $59.69. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a market capitalization of $74.49 billion, a P/E ratio of 20.81, a P/E/G ratio of 1.12 and a beta of 0.56. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the company posted $0.75 earnings per share. The business’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its board has approved a share buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Wolfe Research downgraded Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Stifel Nicolaus set a $60.00 price objective on Boston Scientific in a research note on Wednesday, July 29th. Oppenheimer decreased their price objective on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a report on Monday, July 27th. Evercore set a $65.00 target price on Boston Scientific in a research report on Monday, July 6th. Finally, Daiwa Securities Group cut Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.